Entellus Medical Announces Publication Of Positive Clinical Data For XprESS For Treatment Of Pediatric Chronic Rhinosinusitis

PLYMOUTH, Minn., Nov. 29, 2016 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, today announced that the results of a prospective, multicenter clinical study using the Company's XprESS balloon sinus dilation system in pediatric patients were published in the peer reviewed journal International Forum of Allergy & Rhinology.

The clinical study evaluated fifty pediatric patients suffering from chronic rhinosinusitis (CRS): 33 patients between the ages of 2 and 12 years old, 17 patients older than 12. All patients, who had previously failed medical management, were treated with Entellus Medical's XprESS Multi-Sinus Dilation System with follow-up conducted at one-, three-, and six-months post procedure. Outcome highlights of the study include:
  • 157 sinus dilations were attempted and all were successful;
  • No complications occurred in the study;
  • Significant improvement in the Sinus and Nasal Quality Life Survey (SN-5) was seen for all pediatric patients between baseline and 6 months, 92% improved by a minimal clinically important difference (MCID) of 1.0 or more;
  • Multivariate regression analysis showed no differences or associations of SN-5 improvement at 6 months with the presence of allergy, asthma, or concomitant procedures; and
  • Overall 22-item Sino-Nasal Outcome Test (SNOT-22) mean scores were also significantly improved at 6 months for patients between the ages of 12 and 21.

"The study demonstrates that balloon sinus dilation can be performed safely and successfully on children 2 years and older with CRS," said Zachary M. Soler, MD, MSc, Medical University of South Carolina.  "When chosen correctly, children do appear to have improvements in quality of life up to 6 months following the procedure."

About Entellus Medical, Inc.                                                                                                                               Entellus Medical is a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients.  The Entellus Medical platform of products provides effective and easy-to-use solutions to simplify everything from diagnosis and patient selection, to complex case revisions and post-operative care. Entellus Medical's three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, combine to enable ENT physicians to conveniently and comfortably perform a broad range of procedures in the office and simplify OR based treatment. Entellus Medical is committed to broadening its product portfolios with high-quality and purposeful innovations for the global ENT market. For more information, please visit the Company's website at www.entellusmedical.com.

Forward-Looking Statements: All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the use of words such as "expect," "anticipate," "could," "may," "intend," "will," "estimate," "continue," "outlook," "guidance," "future," other words of similar meaning and the use of future dates.  Forward-looking statements in this release include the Company's financial guidance for full year 2016. These forward-looking statements are based on the current expectations of Entellus Medical's management and involve known and unknown risks and uncertainties that may cause Entellus Medical's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the dependence of the Company's net sales on its XprESS family of products, future market acceptance and adoption of such products and adequate levels of coverage or reimbursement for procedures using such products; the Company's ability to successfully develop and commercialize new ENT products; competition; ability to expand, manage and maintain its direct sales organization and market and sell its products in the United States and internationally; risks and uncertainties involved in its international operations, especially in light of the recent referendum vote of the United Kingdom to exit the European Union; the compliance of its products and activities with the laws and regulations of the countries in which they are marketed;  failure or delay in obtaining FDA or other regulatory approvals or the effect of FDA or other regulatory actions; risks and uncertainties involved in the XeroGel  acquisition, including the failure to realize intended benefits from the transaction or delay in realization thereof, the integration taking longer or being more difficult, time-consuming or costly to accomplish than expected and business disruption after the transaction; the Company's ability to manage its anticipated growth; risk of product recalls, product liability claims and litigation and inadequate insurance coverage relating thereto; intellectual property disputes; loss of key suppliers; inadequacy of capital resources and inability to raise additional financing when needed and on favorable terms. Other factors that could cause actual results to differ materially from those contemplated in this press release can be found under the caption "Risk Factors" in the Company's Securities and Exchange Commission ("SEC") reports, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2015 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2016 to be filed with the SEC. Entellus Medical undertakes no obligation to update or revise any forward-looking statements, even if subsequent events cause its views to change.
Contact: Lynn Pieper Lewis415-937-5402ir@entellusmedical.com

Primary Logo

If you liked this article you might like

Insider Trading Alert - ENTL, AZZ And JCTCF Traded By Insiders

Insider Trading Alert - ENTL, AZZ And JCTCF Traded By Insiders

Insider Trading Alert - EXLS, ENTL And GPRE Traded By Insiders

Insider Trading Alert - EXLS, ENTL And GPRE Traded By Insiders

Entellus Medical (ENTL) Stock Up Today on Trading Debut After Pricing IPO at $17

Entellus Medical (ENTL) Stock Up Today on Trading Debut After Pricing IPO at $17